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The recent description of somatic cell reprogramming to an embryonic stem (ES) cell-like phenotype, termed
induced pluripotent stem (iPS) cell technology, presents an exciting potential venue toward cell-based ther-
apeutics and disease models for neurodegenerative disorders. Two recent studies (Dimos et al. and Ebert
et al.) describe the initial characterization of neurodegenerative disease patient-derived iPS cell cultures
as proof of concept for the utility of this technology.Stem cell-based therapies for neurode-
generative disorders are particularly attr-
active, given the limited regenerative
capacity of the mammalian central ner-
vous system. However, most potential
sources of cell therapeutics, such as
fetal-derived primary neurons, human ES
cells, and endogenous neural stem cells,
are associated with ethical controversy
or present technical limitations. Further-
more, cell therapies from heterologous
sources can be subject to graft rejection,
and attempts to generate immunologi-
cally compatible stem cell therapies by
nuclear transplantation from human cells
(‘‘therapeutic cloning’’) have thus far
been unsuccessful. In this context, Shinya
Yamanaka’s group devised a novel cell-
based screen for the identification of
genes that could directly reprogram skin
fibroblasts to pluripotency (Okita et al.,
2007; Takahashi and Yamanaka, 2006).
Yamanaka and colleagues had assem-
bled a list of 23 candidate ‘‘stemness’’
genes implicated in promoting or main-
taining pluripotency, and although trans-
duction of any single candidate was
ineffective, a minimal set of four genes—
Oct4, Sox2, Klf4, and c-Myc—appeared
sufficient for reprogramming to an iPS
cell phenotype (Okita et al., 2007; Takaha-
shi and Yamanaka, 2006; Wernig et al.,
2007). Differentiation of these iPS cell
cultures generated a variety of cell fates
in vitro and in vivo, and rodent iPS cells
transplanted into blastocysts could
contribute to all tissues, including the
germline. The subsequent successful
generation of human iPS cells from skin
fibroblasts opened the door for iPS cell-based therapies (Takahashi and Yama-
naka, 2006; Yu et al., 2007).
To this end, Dimos et al. (Dimos et al.,
2008) obtained fibroblast lines from two
elderly siblings with early or late manifes-
tations of ALS, including weakness of
the arms and legs, caused by a disease-
associated mutation in the superoxide
dismutase (SOD1) gene. Patient fibro-
blasts were retrovirally transduced with
the Yamanaka group’s four-gene cock-
tail, and after 3 weeks, colonies arose
with a distinctive rounded ES cell-like
morphology and displaying typical ES cell
markers such as alkaline phosphatase
activity and expression of SSEA-3,
SSEA-4, TRA 1-60, and TRA 1-81. These
iPS cell lines appeared to be pluripotent
in vitro, as they could be spontaneously
differentiated into representative pheno-
types of the three embryonic germ cell
layers. Furthermore, using an established
protocol that recapitulates aspects of
endogenous spinal motor neuron specifi-
cation, including the application of reti-
noic acid and an agonist of the Sonic
Hedgehog signaling pathway, iPS cells
could be driven to a spinal motor neuron-
like phenotype. These cells expressed
key motor neuron markers, including
HB9 and ISLET1/2, although they were
not functionally characterized for basic
neuronal properties. A key limitation of
the study is that no phenotypic changes
that may correspond to the disease
process were described.
The study from Ebert et al. (Ebert et al.,
2008) took a very similar approach to
address the major spinal motor neuron
degenerative disorder of childhood, spinalNeuron 61,muscular atrophy, typically caused by
a genetic mutation in the survival motor
neuron-1 (SMN1) gene. Skin fibroblasts
from a single patient and control (his un-
affected mother) were transduced with
a cocktail of lentiviral constructs (Oct4,
Sox2, Nanog, LIN28), leading to the gener-
ation of iPS cell lines, and these could in
turn be differentiated to a variety of cell
types, including cells with a spinal motor
neuron phenotype that harbor the SMN1
mutation. Ebert et al. (Ebert et al., 2008)
went on to culture the iPS cell culture-
derived motor neurons for an additional
2 weeks and reported a specific reduction
in the accumulation and size of these
cells in patient cultures versus normal
controls. In addition, the patient iPS cells
displayed apredicted deficiency in nuclear
SMN protein aggregates, termed gems.
Treatment of the cells with either of two
known chemical inducers of SMN protein
expression—valproic acid or tobramy-
cin—suppressed this phenotype. It will be
of interest to determine whether patient
iPS cell-derived motor neuron reduction
can be similarly suppressed by these
compounds or by novel SMN inducers.
Furthermore, although encouraging, it will
be important to replicate thesedata, which
have been derived from single-patient iPS
cell cultures, as humanEScell linesdisplay
substantial phenotypic diversity, and given
the genetic heterogeneity of these individ-
uals. Ultimately, suppression of patient iPS
cell culture-associated phenotypes by
repair of the underlying genetic mutation
would strongly validate these models.
Despite these concerns, iPScell cultures
offer a potentially powerful approach toFebruary 12, 2009 ª2009 Elsevier Inc. 337
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Existing animal models of neurodegenera-
tion do not recapitulate key aspects of
disease: for instance, mice harboring
genetic mutations that are associated
with familial forms of Parkinson’s disease
fail to display a selective loss of midbrain
substantia nigra dopamine neurons (Abe-
liovich and Flint Beal, 2006), possibly a
consequence of species-specific aspects
of disease. In the context of SMA, patho-
genesis due to SMN1 mutation requires
coexpression of the nearly identical
SMN2 gene, but the latter gene is absent
in model organisms. An additional limita-
tion of existing animal and cell models
of neurodegenerative disease is that
they are generally based on rare familial
inherited forms of these disorders. For
instance, although SOD1 mutations
account for less than 1% of all ALS cases,
nearly all drug discovery efforts for ALS
have been based on this model.
Although the two studies cited here
focused on familial forms of neurodegen-
erative diseases, iPS cell-derived neurons
could also be generated from patients
with common ‘‘sporadic’’ forms of these
diseases. The etiology of ‘‘sporadic’’ dis-
ease is unclear, and there is evidence for
both environmental causes as well as
complex multigenic effects. Studies to
address this issue are typically based on
epidemiological approaches, but iPS cell
models offer an alternative. iPS cell
reprogramming is believed to maintain
genomic content, but to erase epigenetic
signatures, as would arise from environ-
mental or cell-intrinsic stimuli (Okita
et al., 2007; Takahashi et al., 2007; Taka-
hashi and Yamanaka, 2006). Thus, if
common ‘‘sporadic’’ ALS is primarily
due to complex multigenic causes, then
reprogrammed cells may retain an under-
lying propensity for disease. In contrast,
nongenetic or epigenetic causes that are
not encoded in the host genome may be
erased through reprogramming, and iPS
cell generation and neuronal differentia-
tion may ‘‘rejuvenate’’ the cells and thus
be protective in cell-based therapies.
It remains to be determined whether
typical neurodegenerative disease traits
can be observed in the context of iPS
cell-based culture models of these
disorders. At a molecular level, such as
disease-associated protein expression
levels or global gene expression analysis,338 Neuron 61, February 12, 2009 ª2009 Elsit is possible that patient iPS-derived
neuron cultures will recapitulate patient
phenotypes. But for late-onset neurode-
generative diseases, reprogrammed
patient iPS cell-derived neurons are
unlikely to show typical patient brain
pathology, such as Lewy bodies in PD.
The generation of iPS cells from
a patient’s own skin fibroblasts would
potentially allow for a plentiful source of
cell therapeutics for autotransplantation
and would likely mitigate the problem of
immune rejection. Furthermore, iPS cell
technology largely circumvents political,
ethical, and logistical roadblocks previ-
ously associated with human nuclear
transplantation (‘‘therapeutic cloning’’).
However, other concerns remain, such
as the risk of cancer. The Yamanaka
group’s initial studies indicated an
increased risk of tumors in iPScell-derived
mouse progeny, and this correlated with
vector-encoded c-Myc expression in the
tumor cells (Okita et al., 2007). Indeed,
Dimos et al. (Dimos et al., 2008) observe
maintained expression of the virally
encoded c-Myc oncogene in the iPS cell
lines.However, recent studieshaveshown
that c-Myc transduction is expendable
for reprogramming (Nakagawa et al.,
2008; Yu et al., 2007). Retroviral vectors
used for iPS cell generation can also
induce tumorigenesis upon integration
into the host genome, but this can be cir-
cumvented using nonintegrating vectors
(Stadtfeld et al., 2008).
The majority of prior clinical experience
with cellular therapeutics in the CNS
has been based on fetus-derived cells
from postmortem human embryos for
PD patients (Freed et al., 2001). The
results have been largely disappointing:
symptomatic benefit appears variable,
and bothersome dyskinesias can be
seen (Freed et al., 2001). As fetus-derived
dopaminergic cell therapies are obtained
at a relatively late stage of development
and in limited numbers, it is possible that
iPS cell-derived or other stem cell-based
therapeutics would be more effective.
Promising results come from an animal
study in which rodent iPS cell-derived
neurons improve symptoms of rats with
Parkinson’s disease (Wernig et al.,
2008). In contrast, the problem of cell
replacement for spinal motor neurons
appears logistically daunting, given that
these cells must extend and correctlyevier Inc.wire meter-long axons. Transplanting
cell therapeutics as support cells, rather
than as replacement neurons, is a poten-
tial alternative mode of cell therapy.
A final concern is that iPS cell-derived
therapeutics will recapitulate the patient’s
disease process, due to their genetic
propensity. In the context of single-gene
disorders, such changesmay theoretically
be genetically repaired in vitro prior to
transplantation, as suggested by a study
with a rodent model of sickle cell anemia
(Hannaetal., 2007). Fordisordersof aging,
the relatively brief lifetime of the reprog-
rammed cells may sufficiently delay an
intrinsic pathogenic program. However,
cell-extrinsic factors in the host patient
CNS environment may promote patho-
genesis in therapeutic transplanted cells,
as suggested in analysesof autopsymate-
rial from PD patients previously trans-
planted with fetus-derived dopamine
neurons (Li et al., 2008). Despite these
potential pitfalls, iPS cell technology,
although nascent, represents a remark-
able step forward toward stem cell thera-
peuticsandmodels for neurodegenerative
disorders, for which no current therapies
significantly modify disease progression.
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